ArticleFrontiers in endocrinology2025
Case Report: Metreleptin treatment enables successful pregnancy in a female with congenital generalized lipodystrophy.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipodystrophy is a rare group of conditions characterized by partial or total absence of adipose tissue in the body. The lipodystrophy is either congenital or acquired and is also classified further to either generalized or partial. Lipodystrophy is associated with severe insulin resistance and metabolic disorders due to ectopic fat deposition. The therapeutic approach of lipodystrophy is limited to preventing the exacerbation of complications associated to metabolic disorders and include low fat diet and exercise in combination with medication for diabetes control and fibrates or statins to control dyslipidemia. Metreleptin is an adjunctive injectable treatment for people with generalized lipodystrophy due to leptin deficiency aiming to improve appetite and metabolic markers. Metreleptin treatment has also beneficial impact on liver and kidney function, the cardiovascular and the reproductive system and fertility. In the current paper we present a rare case of a female patient of reproductive age with congenital generalized lipodystrophy type 1 who received metreleptin treatment for the control of her diabetes and metabolic disorders. After 13 months of treatment with metreleptin the patient conceived spontaneously and delivered a healthy neonate. This rare and educational case indicates that metreleptin plays a key role in the adipose-mediated regulation of fertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.